Teva pharmaceutical’s Synribo (omacetaxine mepesuccinate) has been approved for the treatment of chronic myelogenous leukemia (CML) for patients who progress after treatment with at least 2 tyrosine kinase inhibitors. The drug’s effectiveness in chronic phase CML was demonstrated by a reduction in the percentage of cells which express the Philadelphia chromosome genetic mutation.  The subcutaneous medication is administered based on a specific protocol and most common side effects includethrombocytopenia, anemia, neutropenia, lymphopenia as well as weakness/fatigue, diarrhea, nausea and injection site reactions.What other medications have recently been approved for the treatment of CML?

For more information see FDA.